Fulcrum Therapeutics Q1 2024 Earnings Report $3.01 -0.08 (-2.59%) As of 03/28/2025 04:00 PM Eastern Earnings HistoryForecast Fulcrum Therapeutics EPS ResultsActual EPS-$0.43Consensus EPS -$0.44Beat/MissBeat by +$0.01One Year Ago EPSN/AFulcrum Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AFulcrum Therapeutics Announcement DetailsQuarterQ1 2024Date5/13/2024TimeN/AConference Call ResourcesPress ReleaseFULC Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads Fulcrum Therapeutics Earnings HeadlinesFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $8.63 Average PT from AnalystsMarch 28 at 1:35 AM | americanbankingnews.comNext-generation CRISPR company raises $68 million, zeroes in on first clinical trialMarch 27 at 10:18 AM | bizjournals.comThe Same Setup That Led to a 131% Gold Surge Is Happening NowHistorically, when confidence in credit markets gets too high, a gold acceleration phase follows… And we’re seeing the same setup playing out again… With central banks piling into gold, inflation lingering, and debt levels soaring, I believe we’re on the verge of another Gold acceleration cycle—and it could happen fast. Back in November, I told folks to “buy the dip” in gold and I sure hope they listened… I cannot promise future returns or against losses, but now I’m giving you another heads-up… I broke down exactly what I am seeing and how anyone with a regular brokerage account can take advantage… Without actually holding any gold…March 29, 2025 | ProsperityPub (Ad)Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research DealMarch 5, 2025 | benzinga.comFulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare ConferenceMarch 4, 2025 | globenewswire.comOpCo reiterates Outperform on Fulcrum given bullish vibes ahead of SCD readoutFebruary 27, 2025 | markets.businessinsider.comSee More Fulcrum Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fulcrum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulcrum Therapeutics and other key companies, straight to your email. Email Address About Fulcrum TherapeuticsFulcrum Therapeutics (NASDAQ:FULC), a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.View Fulcrum Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
